2. Search Result
Search Result
Results for "

ALR

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Fluorescent Dye

8

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150630
    ALR2-IN-1

    		Aldose Reductase Metabolic Disease
    ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC50=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research .
    ALR2-IN-1
  • HY-122652
    MitoBloCK-6

    		Apoptosis Metabolic Disease
    MitoBloCK-6 is a potent Erv1/ALR inhibitor, with an IC50 of 900 nM and 700 nM, respectively. MitoBloCK-6 also inhibits Erv2 (IC50=1.4 μM). MitoBloCK-6 can induce apoptosis via cytochrome c release in hESCs .
    MitoBloCK-6
  • HY-106697
    Ponalrestat
    1 Publications Verification

    ICI 128436

    		 Aldose Reductase Metabolic Disease
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol .
    Ponalrestat
  • HY-155409
    ALR-38

    		Lipoxygenase Inflammation/Immunology
    ALR-38 is a 5-lipoxygenase (5-LOX) inhibitor (IC50: 1.1 μM) with anti-inflammatory activity. ALR-38 effectively reduces ROS levels in neutrophils .
    ALR-38
  • HY-151947
    ALR2-IN-3

    		Aldose Reductase Metabolic Disease
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 22 nM and 116 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications .
    ALR2-IN-3
  • HY-151946
    ALR2-IN-2

    		Aldose Reductase Metabolic Disease
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 27 nM and 228 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications .
    ALR2-IN-2
  • HY-155408
    ALR-27

    		FLAP Inflammation/Immunology
    ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes .
    ALR-27
  • HY-162758
    ALR2-IN-5

    		Aldose Reductase Metabolic Disease
    ALR2-IN-5 (Compound 10a) is an inhibitor of ALR2 with an IC50 value of 99.29 nM. ALR2-IN-5 exhibits hypoglycemic effects and can be utilized in research related to diabetes .
    ALR2-IN-5
  • HY-147977
    ALR1/2-IN-1

    		Aldose Reductase Cancer
    ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitor with IC50 values of 3.26 μM and 3.06 μM against ALR1 and ALR2, respectively. ALR1/2-IN-1 shows anticancer activity .
    ALR1/2-IN-1
  • HY-155407
    ALR-6

    		FLAP Inflammation/Immunology
    ALR-6 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-6 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM and has no significant effect on direct inhibition of 5-LOX .
    ALR-6
  • HY-121933
    IDD388

    		Aldose Reductase Metabolic Disease
    IDD388 is a selective aldose reductase (ALR2) inhibitor with an IC50 of 30 nM. IDD388 displays selectivity for ALR2 over ALR1 (IC50 of 14 μM) .
    IDD388
  • HY-146661
    Aldose reductase-IN-4

    		Aldose Reductase Cancer
    Aldose reductase-IN-4 (compund IIc) is an aldose reductase inhibitor with IC50s of 11.70 μM and 0.98 μM for aldehyde reductase 1 (ALR1) and ALR2, respectively .
    Aldose reductase-IN-4
  • HY-146129
    Aldose reductase-IN-5

    		Aldose Reductase Metabolic Disease
    As an aldose reductase (ALR2) inhibitor, the compound is used to enhance the combination of inhibitory excitability and antioxidant capacity to delay the progress of diabetes complications.
    Aldose reductase-IN-5
  • HY-D0064
    6,7-Dihydroxy-4-coumarinylacetic acid

    		Aldose Reductase Metabolic Disease
    6,7-Dihydroxy-4-coumarinylacetic acid is a potent and selective inhibitor of ALR2. 6,7-Dihydroxy-4-coumarinylacetic acid inhibits ALR2, SDH andALR1 with IC50s of 9.6, 288 and 66.3 μM, respectively. 6,7-Dihydroxy-4-coumarinylacetic acid clearly suppresses galactitol accumulation .
    6,7-Dihydroxy-4-coumarinylacetic acid
  • HY-W011786
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole

    		Others Metabolic Disease
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole is an inhibitor of larval settlement in marine organisms, demonstrating low toxicity while effectively inhibiting the metamorphosis of species such as barnacles, bryozoans, and polychaetes. 2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole also exhibits activity as an aldose reductase (ALR2) inhibitor, indicating potential therapeutic applications in diabetes-related complications.
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: